If our findings are confirmed in other cohorts and experimental studies provide plausible explanation for the attenuation of FGF23 toxicity or its correlated process during long-term uremia, future clinical trials of FGF23-targeted therapy should focus on incident hemodialysis patients rather than prevalent hemodialysis patients. This evidence concerns the gene FGF23 and uremia.